ARTICLE | Clinical News
OSI preclinical data
June 20, 2005 7:00 AM UTC
In a rodent model of diabetes, PSN357 inhibited glycogen phosphorylase and reduced blood glucose levels following acute and chronic dosing. An increase in liver glycogen also was seen in the study, h...